Outcomes
n ART adherence -Measured as the proportion of days covered (PDC), which was calculated as the proportion of days that patients had all components of their ART regimen "on hand" during the followup period.
-ART adherence was dichotomized at ≥ 80 percent (versus < 80 percent) and ≥95 percent (versus <95 percent) according to guideline recommendations and clinical evidence.
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Statistical Analysis n Adherence ≥80 percent and ≥95 percent was evaluated using logistic regressions.
n Adherence analyses excluded patients who were persistent for 30 days or less, as most ART prescriptions had 30 days of supply resulting in 100 percent adherence for these patients. 
METHODS (CONT'D)
n The data used for this study were not originally collected for research purposes and the diagnostic coding on administrative claims is recorded by physicians to support reimbursement, which can result in measurement error.
n The Multi-State Medicaid Database may not be generalizable to the entire U.S. Medicaid population.
n We cannot rule out the possibility of residual confounding from unmeasured variables that affect outcomes and the choice to treat with a guidelinepreferred or non-preferred first-line ART regimen.
LIMITATIONS
n Baseline demographic and clinical characteristics are presented in Table 1 .
n Unadjusted and multivariable-adjusted adherence analyses are presented in Table 2 .
-In the unadjusted analyses, patients initiating EFV/TDF/FTC were most likely to achieve ART PDCs of ≥80% and ≥95%.
-Compared with patients initiating EFV/TDF/FTC, adjusted odds of adherence ≥80 percent were significantly lower in DRV/r + TDF/FTC patients (adjusted odds ratio (AOR) = 0.561, p = 0.045) and trended lower in RAL + TDF/FTC patients (AOR = 0.666, p = 0.273) and ATV/r + TDF/FTC patients (AOR = 0.904, p = 0.610).
-There were no significant differences in the adjusted odds of ≥95 percent adherence, though they trended lower in DRV/r + TDF/FTC patients (AOR = 0.780, p = 0.248) and RAL + TDF/FTC patients (AOR = 0.777, p = 0.339).
